Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Fig. 3

Empagliflozin ameliorates periarterial and tubulointerstitial fibrosis in the kidney. a Representative images show periarterial and b tubulointerstitial fibrosis, assessed by picrosirius red staining (PSR, magnification = 40× and 4×, respectively). The accompanying bar graphs shows semi-quantitative analysis of average PSR stain intensities obtained from five randomly selected regions of interest (n = 7 mice/group). c Western blot analysis shows changes in expression of collagen (Col) Iα1, Col IIIα1, FN (fibronectin) and GAPDH. The accompanying bar graphs (d–f) show quantitative analysis of protein expression normalized to GAPDH. *p < 0.05 vs. CkC; †p < 0.05 vs. DbC. All values are mean ± SE

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840